Alpha fetoprotein targeted T-cell therapy (Adaptimmune)

N/A

Report date: 2022/12/16 11:24:51

Base Information

Drug NameAlpha fetoprotein targeted T-cell therapy (Adaptimmune)
Drug Alias NameAFP SPEAR T-cell therapyAFP TCR-AdaptimmuneAFP TCR (ADP-A2AFP)ADP-A2AFPAFP TCR +[6] 
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > TCR therapyCell and gene therapy > Gene therapy
Mechanisms of ActionGene transferenceAlpha-fetoprotein modulators
TargetsAlpha-fetoprotein
Therapy Area/IndicationsCarcinoma, Hepatocellular
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesUnited KingdomFrance +[4] 
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesAdaptimmune Llc
China Registration ClassN/A

Develop Information

Active CompaniesAdaptimmune Llc
Inactive CompaniesN/A
Active IndicationsCarcinoma, Hepatocellular
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A